215 related articles for article (PubMed ID: 36168189)
1. Osteoporosis Medications Prevent Subsequent Fracture in Frail Older Adults.
Chattaris T; Oh G; Gouskova NA; Kim DH; Kiel DP; Berry SD
J Bone Miner Res; 2022 Nov; 37(11):2103-2111. PubMed ID: 36168189
[TBL] [Abstract][Full Text] [Related]
2. Examining the Effect of Medication Adherence on Risk of Subsequent Fracture Among Women with a Fragility Fracture in the U.S. Medicare Population.
Keshishian A; Boytsov N; Burge R; Krohn K; Lombard L; Zhang X; Xie L; Baser O
J Manag Care Spec Pharm; 2017 Nov; 23(11):1178-1190. PubMed ID: 29083977
[TBL] [Abstract][Full Text] [Related]
3. Effect of Bisphosphonates on Fracture Outcomes Among Frail Older Adults.
Zullo AR; Zhang T; Lee Y; McConeghy KW; Daiello LA; Kiel DP; Mor V; Berry SD
J Am Geriatr Soc; 2019 Apr; 67(4):768-776. PubMed ID: 30575958
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of denosumab, teriparatide, and zoledronic acid among frail older adults: a retrospective cohort study.
Zullo AR; Lee Y; Lary C; Daiello LA; Kiel DP; Berry SD
Osteoporos Int; 2021 Mar; 32(3):565-573. PubMed ID: 33411003
[TBL] [Abstract][Full Text] [Related]
5. Predictors of Hip Fracture Despite Treatment with Bisphosphonates among Frail Older Adults.
Zullo AR; Sorial MN; Lee Y; Lary CW; Kiel DP; Berry SD
J Am Geriatr Soc; 2020 Feb; 68(2):256-260. PubMed ID: 31580488
[TBL] [Abstract][Full Text] [Related]
6. Persistance and Compliance with Osteroporosis Therapies Among Women in a Commercially Insured Population in the United States.
Cheng LI; Durden E; Limone B; Radbill L; Juneau PL; Spangler L; Mirza FM; Stolshek BS
J Manag Care Spec Pharm; 2015 Sep; 21(9):824-33, 833a. PubMed ID: 26308229
[TBL] [Abstract][Full Text] [Related]
7. Utilization of osteoporosis medication after a fragility fracture among elderly Medicare beneficiaries.
Yusuf AA; Matlon TJ; Grauer A; Barron R; Chandler D; Peng Y
Arch Osteoporos; 2016 Dec; 11(1):31. PubMed ID: 27696099
[TBL] [Abstract][Full Text] [Related]
8. The association of adherence to osteoporosis therapies with fracture, all-cause medical costs, and all-cause hospitalizations: a retrospective claims analysis of female health plan enrollees with osteoporosis.
Halpern R; Becker L; Iqbal SU; Kazis LE; Macarios D; Badamgarav E
J Manag Care Pharm; 2011; 17(1):25-39. PubMed ID: 21204588
[TBL] [Abstract][Full Text] [Related]
9. Gender Disparities in Osteoporosis Screening and Management Among Older Adults.
Ramachandran S; Williams SA; Weiss RJ; Wang Y; Zhang Y; Nsiah I; Bhattacharya K
Adv Ther; 2021 Jul; 38(7):3872-3887. PubMed ID: 34053012
[TBL] [Abstract][Full Text] [Related]
10. Patterns of Prescription Drug Use Before and After Fragility Fracture.
Munson JC; Bynum JP; Bell JE; Cantu R; McDonough C; Wang Q; Tosteson TD; Tosteson AN
JAMA Intern Med; 2016 Oct; 176(10):1531-1538. PubMed ID: 27548843
[TBL] [Abstract][Full Text] [Related]
11. Examining the treatment gap and risk of subsequent fractures among females with a fragility fracture in the US Medicare population.
Keshishian A; Boytsov N; Burge R; Krohn K; Lombard L; Zhang X; Xie L; Baser O
Osteoporos Int; 2017 Aug; 28(8):2485-2494. PubMed ID: 28536737
[TBL] [Abstract][Full Text] [Related]
12. Real-world effectiveness of osteoporosis treatments in Germany.
O'Kelly J; Bartsch R; Kossack N; Borchert J; Pignot M; Hadji P
Arch Osteoporos; 2022 Aug; 17(1):119. PubMed ID: 36044096
[TBL] [Abstract][Full Text] [Related]
13. Association of teriparatide adherence and persistence with clinical and economic outcomes in Medicare Part D recipients: a retrospective cohort study.
Hazel-Fernandez L; Louder AM; Foster SA; Uribe CL; Burge RT
BMC Musculoskelet Disord; 2013 Jan; 14():4. PubMed ID: 23281846
[TBL] [Abstract][Full Text] [Related]
14. Increased fracture risk after discontinuation of anti-osteoporosis medications among hip fracture patients: A population-based cohort study.
Fu SH; Wang CY; Hung CC; Lee CC; Yang RS; Huang CC; Farn CJ; Lin WH; Chen HM; Hsiao FY; Lin JW; Li CY
J Intern Med; 2021 Dec; 290(6):1194-1205. PubMed ID: 34237171
[TBL] [Abstract][Full Text] [Related]
15. The Effectiveness of a Private Orthopaedic Practice-Based Osteoporosis Management Service to Reduce the Risk of Subsequent Fractures.
Sietsema DL; Araujo AB; Wang L; Boytsov NN; Pandya SA; Haynes VS; Faries DE; Taylor KA; Baser O; Jones CB
J Bone Joint Surg Am; 2018 Nov; 100(21):1819-1828. PubMed ID: 30399076
[TBL] [Abstract][Full Text] [Related]
16. Medication persistence and risk of fracture among female Medicare beneficiaries diagnosed with osteoporosis.
Liu J; Guo H; Rai P; Pinto L; Barron R
Osteoporos Int; 2018 Nov; 29(11):2409-2417. PubMed ID: 30022254
[TBL] [Abstract][Full Text] [Related]
17. Fractures and mortality in relation to different osteoporosis treatments.
Yun H; Delzell E; Saag KG; Kilgore ML; Morrisey MA; Muntner P; Matthews R; Guo L; Wright N; Smith W; Colón-Emeric C; O'Connor CM; Lyles KW; Curtis JR
Clin Exp Rheumatol; 2015; 33(3):302-9. PubMed ID: 25068266
[TBL] [Abstract][Full Text] [Related]
18. Denosumab treatment lapses, discontinuation, and off-treatment fracture risk: A retrospective study of patients with osteoporosis in a real-world clinical setting.
Cruchelow KR; Peter ME; Chakrabarti A; Gipson HM; Gregory WT; DeClercq J; Choi L; Tanner SB
Bone; 2023 Dec; 177():116925. PubMed ID: 37797711
[TBL] [Abstract][Full Text] [Related]
19. Incidence of bone protection and associated fragility injuries in patients with proximal femur fractures.
Aguado-Maestro I; Panteli M; García-Alonso M; Bañuelos-Díaz A; Giannoudis PV
Injury; 2017 Dec; 48 Suppl 7():S27-S33. PubMed ID: 28851521
[TBL] [Abstract][Full Text] [Related]
20. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
Davis S; Simpson E; Hamilton J; James MM; Rawdin A; Wong R; Goka E; Gittoes N; Selby P
Health Technol Assess; 2020 Jun; 24(29):1-314. PubMed ID: 32588816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
